ReviewBiomarker research2019

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer.

Zhe Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.